Drug development for intraperitoneal chemotherapy against peritoneal carcinomatosis from gastrointestinal cancer.
about
Treatment of gastric outlet obstruction that results from unresectable gastric cancer: Current evidenceGene therapy with SOCS1 for gastric cancer induces G2/M arrest and has an antitumour effect on peritoneal carcinomatosis.Potentiation of chemotherapeutics by bromelain and N-acetylcysteine: sequential and combination therapy of gastrointestinal cancer cells.Water-soluble and amphiphilic phospholipid copolymers having 2-methacryloyloxyethyl phosphorylcholine units for the solubilization of bioactive compounds.High Penetration of Paclitaxel in Abdominal Wall of Rabbits after Hyperthermic Intraperitoneal Administration of Nab-Paclitaxel Compared to Standard Paclitaxel Formulation.Microniosomes for concurrent doxorubicin and iron oxide nanoparticles loading; preparation, characterization and cytotoxicity studies.
P2860
Drug development for intraperitoneal chemotherapy against peritoneal carcinomatosis from gastrointestinal cancer.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Drug development for intraperi ...... from gastrointestinal cancer.
@en
type
label
Drug development for intraperi ...... from gastrointestinal cancer.
@en
prefLabel
Drug development for intraperi ...... from gastrointestinal cancer.
@en
P2093
P2860
P1433
P1476
Drug development for intraperi ...... from gastrointestinal cancer.
@en
P2093
Eiji Sunami
Hironori Yamaguchi
Joji Kitayama
Shigenobu Emoto
Soichiro Ishihara
Toshiaki Watanabe
P2860
P304
P356
10.1007/S00595-014-0848-X
P577
2014-02-01T00:00:00Z